Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Instagram Outage Disrupts Thousands of U.S. Users 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Reckitt Benckiser is considering the sale of its subsidiary, Mead Johnson Nutritionals, which is based in China. It was said that the British multinational consumer goods company is eyeing at least $2 billion for the deal.
Sources who have knowledge on the matter told Reuters that Reckitt Benckiser already hired the American financial services company, Morgan Stanley, to review its Mead Johnson infant formula unit in Greater China. The insiders were not names since the information shared is confidential.
The plans for the sale of Mead Johnson’s infant formula
Based on the report, Reckitt Benckiser could commence the sale process any time within the second quarter of this year. As soon as the bank receives feedback or recommendation from potential buyers, the sale will begin.
Then again, all the interested parties have been warned that Reckitt Benckiser has not made any definite decision yet, and business valuation could still change because of the negative effects of the COVID-19 pandemic. Moreover, in February, it was said that the company is exploring its other options on how to handle Mead Johnson’s infant formula unit.
In any case, Reckitt Benckiser acquired Mead Johnson in 2017 for $16.6 billion in 2017. The infant formula-maker gave the company billions from the sale of its leading milk brands that include Lactum, Enfapro, and Enfamil.
Why Mead Johnson is being sold
Reckitt Benckiser’s chief executive officer, Laxman Narasimhan, said that there is a big decline in sales in China which makes up 6 percent of the group sales. The reason for the dive is the closure of the Hong Kong border that is taking a long time to re-open due to coronavirus.
Also, the birth rate in one of the most populous countries in the world has gone down as well, so there is less infant to feed with the formula from Mead Johnson. Lastly, Chinese locals have been choosing to buy imported milk due to the 2008 milk contamination controversy scandal. In fact, it was noted that on China’s leading e-commerce platform, JD.Com, the top four best-selling brands of infant formula are all from foreign labels.
